FB102 (Anti-CD122 Antibody)

May 11, 2026 — Forte Biosciences, Inc. (NASDAQ: FBRX) reported first-quarter 2026 financial results and provided a business update focused on FB102, its anti-CD122 monoclonal antibody candidate for autoimmune and autoimmune-related diseases. The company announced that FB102 received FDA Fast Track designation for celiac disease, supporting an accelerated regulatory pathway for a high-unmet-need indication.

Forte said FB102 clinical development is progressing: topline results from the Phase 2 celiac disease study are expected in 2026; Phase 1b topline results in vitiligo are expected “shortly”; and a Phase 1b alopecia areata readout is expected in 2026.

Financially, R&D expense rose to $20.5 million (vs. $12.7 million in Q1 2025), driven mainly by higher clinical spending for FB102 trials. G&A expense decreased to $2.0 million (vs. $3.4 million), primarily due to a $2.3 million interim legal settlement payment under an insurance reservation of rights. Net loss was $22.1 million ($1.24/share). Cash and equivalents were $58.2 million at March 31, 2026; in April 2026, Forte raised $172.5 million gross through an equity offering.